Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double- Blind, Multi-center, Double Dummy, Clinical Trial Comparing HL-040XC With Single Component Therapies(Atorvastatin, Losartan) to Assess the Efficacy and Safety of HL-040XC in Patients With Essential Hypertension and Hyperlipidemia

NCT01541943 is registered in ClinicalTrials.gov with HanAll BioPharma Co., Ltd. as lead sponsor.

NCT NCT01541943
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01541943 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double- Blind, Multi-center, Double Dummy, Clinical Trial Comparing HL-040XC With Single Component Therapies(Atorvastatin, Losartan) to Assess the Efficacy and Safety of HL-040XC in Patients With Essential Hypertension and Hyperlipidemia
Lead sponsor
HanAll BioPharma Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2012
Completion date
November 30, 2014
Enrollment
356 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

essential hypertension, hyperlipidemia